The advisory committee meeting (adcom) that slowed progress for Amarin Corp. and its pending supplemental new drug application (sNDA) for expanding the labeling of Vascepa (icosapent ethyl) was a shock not only to the company but to investors, too, as the stock (NASDAQ:AMRN) took a battering Friday.